An open study with reversible MAO-A inhibitors in complicated Parkinson's disease

Adv Neurol. 1996:69:595-8.

Authors

S Ruggieri¹, G Fabbrini, L Bramante, F DePandis, F Stocchi, P Barbanti, L Vacca, M Manfredi

Affiliation

¹ Mediterranean Institute of Neuroscience, Sanatrix, Pozzilli (IS), Italy.

PMID: 8615185

No abstract available

Publication types

Clinical Trial

MeSH terms

Antiparkinson Agents / therapeutic use
Benzamides / adverse effects
Benzamides / therapeutic use*
Dopamine Agonists / therapeutic use
Drug Therapy, Combination
Humans
Levodopa / therapeutic use
Middle Aged
Moclobemide
Monoamine Oxidase Inhibitors / adverse effects
Monoamine Oxidase Inhibitors / therapeutic use*
Movement Disorders / drug therapy
Movement Disorders / etiology
Parkinson Disease / complications
Parkinson Disease / drug therapy*

Substances

Antiparkinson Agents
Benzamides
Dopamine Agonists
Monoamine Oxidase Inhibitors
Levodopa
Moclobemide